Business & Finance

Who is Lindsay Rosenwald?

User Avatar
Wiki User
2013-10-18 10:25:38

Dr. Lindsay Rosenwald is a research physician

and biotechnology investor based in New York. He spends much of his

time directly involved with the management of biotechnology

oriented hedge funds.

Rosenwald holds a degree in finance from Penn

State and a Doctor of Medicine degree from Temple University. He

completed his internship at Abington Memorial Hospital and later

ran his own private medical practice. He then shifted his focus to

Wall Street where he worked as a physician/analyst. Notably, Dr.

Lindsay Rosenwald was one of the first physician/analysts in the

country to work on Wall Street.

Dr. Lindsay Rosenwald has founded a number of

biotechnology companies. These companies have licensed more than

100 developmental-stage medicines, many of which have been approved

by the U.S. Food and Drug Administration. Lindsay Rosenwald is

perhaps best known for his role in the development of abiraterone

acetate, a drug that has been used successfully to treat pre-and

post-chemotherapy prostate cancer in the United States. Rosenwald

has also been a key figure in getting drugs approved for infant

respiratory distress syndrome, influenza, fibromyalgia, obesity and

schizophrenia.

Lindsay Rosenwald founded Cougar

Biotechnology-the company that managed the development and research

of abiraterone acetate. During the early clinical testing phase of

the drug, Cougar Biotechnology was purchased by Johnson &

Johnson for nearly $1 billion. Abiraterone acetate is on target to

become a multibillion-dollar medication in the coming years. Its

trade name is called "Zytiga". Dr. Lindsay Rosenwald is also

credited for the conception of Trisenox, an arsenic trioxide

injection used to promote the remission of acute promyelocytic

leukemia.

In 2009, Rosenwald and his business partner

founded Investment Partnership, a company that invests in life

sciences and health-care companies. Lindsay Rosenwald established

the company on the belief that health care is an ever-changing

field and that returns can be generated by identifying undervalued,

publicly traded biotech companies. For his advancements in the

field of biomedicine, Dr. Rosenwald was featured in 2002's edition

of Genetic Engineering News as No. 1 in its Top 100

Molecular Millionaire lineup.

Throughout his career, the contributions Dr.

Rosenwald has made to medicine have saved thousands of lives and

improved the quality of life for countless more. He has been

significantly involved in founding a number of organizations in the

field including Cypress Biosciences, Javelin Pharmaceuticals,

BioCryst, and Titan Pharmaceuticals. Prior to his current role at

Investment Partnership, Dr. Lindsay Rosenwald held the distinction

of serving as director of Cougar Biotech,and Keryx

Biopharmaceuticals. Dr. Rosenwald serves on the Columbia

Presbyterian Health Sciences Advisory Council.


Copyright © 2020 Multiply Media, LLC. All Rights Reserved. The material on this site can not be reproduced, distributed, transmitted, cached or otherwise used, except with prior written permission of Multiply.